SARS-CoV-2 Neutralizing Antibodies in Chile after a Vaccination Campaign with Five Different Schemes
Date
2022
Type:
Article
item.page.extent
7 p.
item.page.accessRights
Acceso abierto
item.contributor.advisor
ORCID:
Journal Title
Journal ISSN
Volume Title
Publisher
item.page.isbn
item.page.issn
item.page.issne
item.page.doiurl
item.page.other
item.page.references
Abstract
Using levels of neutralizing antibodies (nAbs), we evaluate the successful Chilean SARS-CoV-2 vaccine campaign, which combines different vaccine technologies and heterologous boosters.
From a population-based study performed in November 2021, we randomly selected 120 seropositive individuals, organized into six groups of positive samples (20 subjects each) according to natural
infection history and the five most frequent vaccination schemes. We conclude that the booster dose, regardless of vaccine technology or natural infection, and mRNA vaccines significantly improve
nAbs response.
Description
item.page.coverage.spatial
item.page.sponsorship
Citation
Aguilera, X.; Hormazábal, J.; Vial, C.; Cortes, L.J.; González, C.; Rubilar, P.; Apablaza, M.; Ramírez-Santana, M.; Icaza, G.; Nuñez-Franz, L.; et al. SARS-CoV-2 Neutralizing Antibodies in Chile after a Vaccination Campaign with Five Different Schemes. Vaccines 2022, 10, 1051. https://doi.org/10.3390/ vaccines10071051
Keywords
neutralizing antibodies; vaccines; BNT162b2; CoronaVac; AZD1222; COVID-19; SARS-CoV-2; cross-sectional design; vaccine-preventable diseases; viruses, Vaccines, BNT162b2, CoronaVac, AZD1222, Covid-19, Sars-CoV-2, Cross-sectional design, Vaccine-preventable diseases, Viruses